US Patent 8,481,598: Levomilnacipran 120 mg Sustained-Release Treatment Claims and Patent Landscape
US Patent 8,481,598 protects a method of treating major depressive disorder with approximately 120 mg/day of levomilnacipran, preferably levomilnacipran hydrochloride, delivered through one or more sustained-release oral dosage forms. The core claim is limited by dose, dosage form, 24-hour exposure, pharmacokinetic parameters, and, in dependent claims 7 and 8, control of a specific process-related impurity.
The patent is a method-of-use and pharmacokinetic patent. It does not, based on the supplied claims, broadly claim levomilnacipran as a molecule, every levomilnacipran formulation, or every dose used to treat depression.
What does US Patent 8,481,598 protect?
The independent claim requires all of the following:
| Limitation |
Claim requirement |
| Disease |
Major depressive disorder |
| Patient |
A patient in need of treatment |
| Active ingredient |
Levomilnacipran or a pharmaceutically acceptable salt |
| Dose |
About 120 mg/day |
| Dosage form |
One or more sustained-release oral dosage forms |
| Exposure duration |
Therapeutic plasma level over approximately 24 hours |
| Cmax |
About 50 to about 350 ng/mL |
| AUC0-∞ |
About 1,000 to about 9,000 ng·hr/mL |
| Tmax |
At least 3 hours |
A generic or follow-on product would face infringement risk only if its use falls within the complete combination of these limitations. A product containing levomilnacipran is not automatically within the claim. The asserted treatment must involve the claimed dose, sustained-release oral delivery, disease indication, and pharmacokinetic profile.
The patent issued July 9, 2013, from an application directed to methods for treating depression with levomilnacipran. The listed patent term is generally associated with expiration in September 2027, subject to the patent’s recorded term adjustment and any applicable regulatory exclusivity. The controlling expiration date should be confirmed against the current USPTO patent record and FDA Orange Book listing before a launch or freedom-to-operate decision. [1][2]
How do claims 1 through 6 define the pharmacokinetic scope?
Claims 1 through 6 define the invention primarily through exposure rather than tablet composition.
Claim 1: broadest enforceable combination
Claim 1 requires:
- approximately 120 mg/day;
- sustained-release oral administration;
- approximately 24-hour therapeutic exposure;
- Cmax from about 50 to about 350 ng/mL;
- AUC0-∞ from about 1,000 to about 9,000 ng·hr/mL; and
- Tmax of at least 3 hours.
The ranges are broad. The Cmax range spans a sevenfold interval, while the AUC range spans a ninefold interval. The most commercially meaningful limitation is likely the combined requirement of the 120 mg/day dose, sustained release, and delayed Tmax.
A product may avoid the claim if it produces a Tmax below 3 hours, produces a materially different Cmax or AUC, uses immediate-release delivery, or is labeled for a different indication and does not induce the claimed method of treatment.
Claims 3 and 4: narrower exposure profiles
Claim 3 narrows Tmax to a mean of approximately 4 to 10 hours.
Claim 4 requires:
- mean Tmax of at least 3 hours; and
- mean AUC0-∞ from approximately 5,000 to 9,000 ng·hr/mL.
These limitations focus on the average exposure profile across a patient population or pharmacokinetic study. They may be relevant to products engineered to provide a full-day release profile rather than simply a delayed-release dosage form.
Claims 5 and 6: AUC centered around 5,000 ng·hr/mL
Claim 5 requires a mean Tmax of at least 3 hours and mean AUC0-∞ within 10% of 5,000 ng·hr/mL. Numerically, the claimed AUC is approximately 4,500 to 5,500 ng·hr/mL.
Claim 6 uses a 20% tolerance, corresponding approximately to 4,000 to 6,000 ng·hr/mL.
The range in claim 5 is nested within claim 6 for the overlapping region. Claims 5 and 6 could become important in a case involving a product with an average AUC close to 5,000 ng·hr/mL but with a different release mechanism or excipient system.
The text supplied for claims 5 and 6 uses “AUG0-∞.” In context, this appears to be a drafting or transcription error for “AUC0-∞,” the standard pharmacokinetic measure of area under the plasma concentration-time curve. The issued patent text should control claim construction. [1]
What formulation and impurity limitations are protected?
Claims 7 and 8 add a chemical-purity limitation involving:
“(1S,5R) 1-phenyl-3-azabicyclo[3-1-0]hexane-2-one.”
This compound is claimed at a specified percentage by weight relative to levomilnacipran or its salt:
| Claim |
Impurity range |
| Claim 7 |
About 0.001% to about 0.5% by weight |
| Claim 8 |
About 0.001% to about 0.2% by weight |
These claims do not independently claim a composition. They apply only when the product is administered in the method of claim 1 and contains the specified impurity within the stated range.
The impurity limitation creates a potentially significant analytical issue. A generic applicant would need to characterize:
- whether the impurity is present;
- the impurity’s stereochemical identity;
- its concentration relative to levomilnacipran or levomilnacipran hydrochloride;
- batch-to-batch variation;
- degradation during stability testing; and
- whether the claimed range is met in the finished dosage form.
The ranges are unusual from an infringement perspective because they include very low concentrations. A product intentionally purified below 0.001% could potentially avoid claims 7 and 8, but it would still need to avoid the broader limitations of claim 1.
Is US 8,481,598 a composition patent or a method-of-use patent?
US 8,481,598 is principally a method-of-use patent with pharmacokinetic limitations.
| Patent category |
Covered by the supplied claims? |
| Levomilnacipran molecule |
No broad molecular claim is supplied |
| Levomilnacipran hydrochloride |
Yes, through dependent claim 2 |
| Sustained-release oral administration |
Yes |
| Treatment of major depressive disorder |
Yes |
| 120 mg/day dosing |
Yes |
| Pharmacokinetic profile |
Yes |
| Specific impurity level |
Yes, claims 7 and 8 |
| Every levomilnacipran dosage |
No |
| Immediate-release formulation |
No, based on the supplied claims |
| Other indications |
No, based on the supplied claims |
The distinction matters under US generic-drug law. A formulation manufacturer may avoid direct infringement if its product cannot meet the claimed pharmacokinetic and dosing limitations. A generic applicant may also use a section viii statement to carve out a patented method of use if the FDA-approved labeling can omit the protected indication or dosing instruction. Whether a carve-out is viable depends on the Orange Book listing, approved labeling, regulatory requirements, and the specific product’s use.
What is the Orange Book and FDA status of levomilnacipran?
Fetzima is the branded extended-release levomilnacipran hydrochloride product marketed for major depressive disorder. FDA approved Fetzima in 2013. The approved dosage is titrated from a lower starting dose, with a maximum recommended dose of 120 mg once daily. The product is supplied as extended-release capsules. [3]
The FDA label identifies the following strengths:
| Product |
Dosage form |
Strengths |
| Fetzima |
Extended-release capsule |
20 mg, 40 mg, 80 mg, 120 mg |
The 120 mg once-daily regimen corresponds closely to the dose limitation in claim 1. The extended-release capsule corresponds to the sustained-release oral dosage-form limitation.
The Orange Book analysis should separate:
- patents listed against the reference product;
- patents directed to the active ingredient;
- formulation patents;
- method-of-use patents;
- pediatric exclusivity;
- new chemical entity or other regulatory exclusivity; and
- current delisting or expiration status.
Patent 8,481,598 should not be treated as the entire Fetzima patent estate. An ANDA applicant must assess every listed patent and every relevant unlisted patent, including manufacturing, polymorph, salt, formulation, impurity, and process patents. [2]
When does levomilnacipran lose patent and regulatory exclusivity?
The principal statutory patent date associated with US 8,481,598 is September 2027, subject to the patent’s recorded term adjustment. FDA regulatory exclusivity is separate from patent term.
| Protection |
Relevance |
| US 8,481,598 |
Method-of-use and pharmacokinetic protection |
| Expected patent horizon |
Approximately September 2027, subject to official term calculation |
| FDA approval |
2013 |
| Pediatric exclusivity |
Must be checked in the current Orange Book |
| NCE exclusivity |
Historic five-year period would have expired before the current patent horizon |
| ANDA approval timing |
May depend on certification, litigation, settlement, and listed-patent status |
Patent expiration does not guarantee immediate generic marketing. A generic applicant may be blocked by another unexpired listed patent, a settlement agreement, a court injunction, regulatory exclusivity, or a product-specific manufacturing patent.
What Paragraph IV challenges and patent litigation affect Fetzima?
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. For this patent, the most likely technical disputes would concern:
- whether the proposed dose is “about 120 mg/day”;
- whether the dosage form is sustained release;
- whether the proposed regimen produces the claimed Cmax, AUC, and Tmax;
- whether the pharmacokinetic data are measured in the relevant patient population;
- whether the claims require the branded indication to be present in the proposed label;
- whether the impurity is the claimed stereoisomer; and
- whether the impurity concentration falls within the claimed relative-weight range.
A method-of-use patent can be challenged through an ANDA certification even where the applicant proposes a product with a label that does not expressly include the patented use. The strength of that defense depends on inducement allegations and whether the proposed labeling, promotional materials, or ordinary use would encourage the patented regimen.
The supplied patent information does not establish a current Paragraph IV filing, district-court complaint, settlement, or launch date. The patent document itself does not provide that procedural status. Current litigation review requires the FDA Orange Book, FDA Paragraph IV notices where available, PACER, district-court dockets, and settlement disclosures.
How strong is the patent estate for levomilnacipran?
US 8,481,598 has moderate claim breadth but meaningful commercial relevance.
Strengths
- The claim tracks the branded product’s 120 mg extended-release regimen.
- It combines dose, disease, dosage form, and pharmacokinetic limitations.
- Claims 3 through 6 provide multiple narrower exposure targets.
- Claims 7 and 8 add a product-quality limitation that may be difficult to assess without access to batch data.
- The patent can create inducement and labeling risk even if the active ingredient itself is no longer protected.
Vulnerabilities
- The claim requires proof of several cumulative limitations.
- Pharmacokinetic ranges can create noninfringement opportunities.
- “About” and “approximately” introduce claim-construction disputes.
- Method claims generally do not block all sales of the active ingredient.
- A generic applicant may seek a label carve-out for the patented method.
- The impurity claims depend on analytical testing and may not cover a highly purified alternative process.
- The claims do not, on their face, cover immediate-release products or doses materially below 120 mg/day.
The patent is stronger against a generic product deliberately designed to replicate Fetzima’s 120 mg extended-release exposure profile. It is weaker against a product with a different release profile, different labeled dose, different indication strategy, or impurity profile outside claims 7 and 8.
How does the patent compare with likely competing protection types?
| Protection type |
Typical scope |
Relationship to US 8,481,598 |
| Active-ingredient patent |
Covers levomilnacipran or a salt |
Potentially broader, but not established by the supplied claims |
| Formulation patent |
Covers excipients, release matrix, coating, or capsule |
May block a product even if it avoids the method claim |
| Method-of-use patent |
Covers treatment of a defined condition |
US 8,481,598 falls primarily in this category |
| Pharmacokinetic patent |
Covers target exposure parameters |
Central feature of US 8,481,598 |
| Process patent |
Covers synthesis or purification |
May create manufacturing barriers |
| Impurity patent |
Covers impurity level or control |
Claims 7 and 8 add this layer |
| Regulatory exclusivity |
Delays FDA approval or marketing |
Separate from patent rights |
A complete freedom-to-operate opinion therefore requires more than reviewing the ’598 patent. It must map the Orange Book-listed patents and relevant non-listed rights against the proposed active ingredient, salt, manufacturing route, release technology, dosage, label, and launch jurisdiction.
What generic launch scenarios exist?
Scenario 1: Full-label generic after patent expiry
A generic applicant markets a 120 mg extended-release levomilnacipran product after all relevant patents and exclusivities expire. This is the lowest legal-risk pathway but may produce the latest entry date.
Scenario 2: Paragraph IV challenge
The applicant certifies that the ’598 patent is invalid, unenforceable, or not infringed. Litigation may delay approval or launch. A successful challenge could support an earlier launch, while an adverse judgment could preserve the patent through expiration.
Scenario 3: Section viii carve-out
The applicant omits the patented major-depressive-disorder use or the specific protected dosing information from its label, if FDA permits the carve-out. The commercial scope may be narrower, and inducement risk remains relevant.
Scenario 4: Design-around formulation
The applicant uses a release profile that does not meet the claimed Tmax or exposure ranges, or uses a dose outside the claimed approximately 120 mg/day regimen. This approach requires reliable clinical and pharmacokinetic data.
Scenario 5: Purity-based design-around
The applicant controls the specified impurity below 0.001% or outside the claimed ranges. This may avoid claims 7 and 8, but it does not avoid claim 1 unless the other method limitations are also absent.
Key Takeaways
- US 8,481,598 is a method-of-use patent centered on 120 mg/day sustained-release levomilnacipran for major depressive disorder.
- Claim 1 requires a specific pharmacokinetic profile: Cmax, AUC0-∞, and Tmax limitations.
- Claims 3 through 6 narrow the exposure profile and may matter in product-specific infringement analysis.
- Claims 7 and 8 target a defined stereochemical impurity concentration.
- The patent does not broadly claim every levomilnacipran product or every levomilnacipran treatment regimen.
- The expected patent horizon is approximately September 2027, subject to official USPTO term calculations.
- A generic strategy could involve Paragraph IV litigation, a section viii carve-out, a different release profile, a different dose, or impurity control.
- The ’598 patent should be analyzed with the full Orange Book patent listing and any relevant formulation, process, salt, polymorph, and manufacturing patents.
FAQs
Does US 8,481,598 cover levomilnacipran immediate-release tablets?
Not based on the supplied claims. Claim 1 requires one or more sustained-release oral dosage forms.
Does a 40 mg or 80 mg product infringe claim 1?
The supplied claim requires approximately 120 mg/day. A 40 mg or 80 mg regimen would generally fall outside that dose limitation, although other patents or claims could apply.
Can a generic omit the major depressive disorder indication?
Potentially, through a section viii label carve-out if FDA accepts the proposed labeling and the generic’s conduct does not induce the patented use. The result depends on the approved labeling and the complete patent listing.
Do claims 7 and 8 cover the levomilnacipran impurity itself?
They cover administering a sustained-release levomilnacipran product containing the specified impurity within a defined concentration range. They are not standalone composition claims based on the supplied text.
Does patent expiration automatically permit a generic launch?
No. Other patents, regulatory exclusivity, litigation outcomes, injunctions, settlements, or manufacturing rights may affect launch timing.
References
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,481,598, methods for treating depression with levomilnacipran.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2013). Fetzima (levomilnacipran hydrochloride) extended-release capsules prescribing information.
